Peritoneal dialysis in acute kidney injury: twenty years of experience at a single center in a developing country - Journal of Nephrology Background This study aimed to explore the role of peritoneal dialysis (PD) in patients with acute kidney injury (AKI) in relation to metabolic and fluid control, outcome and risk factors for death. M...

🔬A 20-year study in the Journal of Nephrology highlights the burden of AKI in critical care.

Arch is supporting two Phase II trials targeting CS-AKI and DI-AKI. Arch’s clinical programs (archbiopartners.com/our-science)

#AKI #TrialRationale #ArchScience

Full – doi.org/10.1007/s40620-024-02189-y

Optimizing the Design and Analysis of Future AKI Trials : Journal of the American Society of Nephrology ical thresholds. Heterogeneity in the pathobiology, etiology, presentation, and clinical course of AKI remains a key challenge in successfully testing new approaches for AKI prevention and treatment. ...

🔍 A 2022 JASN consensus (doi.org/10.1681/asn.2021121605) calls for AKI trials focused on clear subtypes like CS-AKI, with better biomarkers and endpoints.

Arch is supporting two Phase II trials for CS-AKI and DI-AKI.

🔬 archbiopartners.com/our-science

#AKI #CSAKI #TrialRationale #ArchBiopartners

Cardiac and Vascular Surgery–Associated Acute Kidney Injury: The 20th International Consensus Conference of the ADQI (Acute Disease Quality Initiative) Group | Journal of the American Heart Associatio...

🫀 A 2018 international consensus led by ADQI (doi.org/10.1161/JAHA.118.008834) cites inflammation, IRI, and toxins as causes of AKI.

These drivers match the targets of Arch Biopartners’ clinical strategy.

📖 Learn more: archbiopartners.com/our-science

#CSAKI #AKI #TrialRationale #KidneyCare

Our Science – Arch Biopartners

🌐 Cardiac surgery demand exceeds global capacity 12-to-1 (June 2024 - doi.org/10.1016/j.atssr.2023.11.019).

As access grows, so does the burden of CS-AKI—and the need for prevention.

📖 Learn more: archbiopartners.com/our-science

#ArchBiopartners #CSAKI #TrialRationale #ArchScience #InvestorFAQ

Practice Variation in Cardiac Surgery and Acute Kidney Injury This cohort study assesses operating room practices for vasopressor infusions, inotrope infusions, red blood cell transfusions, and fluid volume administration and their association with postsurgical ...

🩺 A 2025 JAMA Network Open study (doi.org/10.1001/jamanetworkopen.2025.8342) finds CS-AKI rates vary widely—11.7% to 32.8%—driven by intraoperative practices.

🔔 How Arch is addressing AKI in cardiac surgery: archbiopartners.com/our-science

#CSAKI #AKI #ArchScience #TrialRationale #KidneyCare

🩺 A 2025 review (doi.org/10.36348/sjmps.2025.v11i03.009 - PDF) finds ICU trauma patients are at high risk for AKI due to rhabdomyolysis, obesity, and hemodynamic stress.

🔔 More about Arch's work to prevent AKI: archbiopartners.com/our-science

#ArchBiopartners #AKI #ArchScience #TrialRationale

(PDF) Combination of urinary biomarkers can predict cardiac surgery-associated acute kidney injury: a systematic review and meta-analysis PDF | Introduction Acute kidney injury (AKI) develops in 20–50% of patients undergoing cardiac surgery (CS). We aimed to assess the predictive value of... | Find, read and cite all the research you ne...

🧪 A recent meta-analysis supports the use of urinary biomarkers to predict AKI after cardiac surgery.
Findings align with Arch’s CS-AKI trial with LSALT peptide.

📖 Full study www.researchgate.net/publication/...

More at archbiopartners.com/our-science

#ArchBiopartners #CSAKI #AKI #TrialRationale